AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23347693 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 54 mg/day
Number of subjects: 276
Study 23347693 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 72 mg/day
Number of subjects: 276
Study 23347693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 23347693 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH (54 mg and 72 mg)
Number of subjects: 276
Study 21989464 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 80711
Study 21989464 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no statin
Number of subjects: 80711
Study 18027125 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative age stereotype
Number of subjects: 0
Study 18027125 — intervention group
Group type: COMPARATOR
Intervention: Positive age stereotype
Number of subjects: 0
Study 16551903 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine peribulbar block with general anesthesia
Number of subjects: 62
Study 16551903 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with subcutaneous normal saline injection
Number of subjects: 62
Study 12135445 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid iontophoresis
Number of subjects: 64
Study 12135445 — intervention group
Group type: COMPARATOR
Intervention: Placebo iontophoresis
Number of subjects: 64
Study 10447245 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt with an iodine concentration of 25 ppm (Group A)
Number of subjects: 0
Study 10447245 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized oil capsules containing 400 mg iodine (Group C)
Number of subjects: 0
Study 10447245 — intervention group
Group type: EXPERIMENTAL
Intervention: Market-purchased iodized salt (Group B)
Number of subjects: 0
Study 7599866 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human tumor necrosis factor-alpha (rhTNF alpha) 60 ng
Number of subjects: 8
Study 7599866 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study 2347435 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g/kg ethanol
Number of subjects: 15
Study 2347435 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 15
Study 117999 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH perfusions (1,200 micrograms)
Number of subjects: 0
Study 117999 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH perfusions
Number of subjects: 0
Study 28768370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline 10 mg once daily
Number of subjects: 61
Study 28768370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 27920241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (monthly group sessions for 3 consecutive months)
Number of subjects: 160
Study 24820465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate at 2.4 mg/kg at 0, 12, and 24 hours, then daily
Number of subjects: 94
Study 24820465 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine at a 20 mg/kg loading dose, then 10 mg/kg three times a day
Number of subjects: 94
Study 24820465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 94
Study 24820465 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 94
Study 24820465 — intervention group
Group type: COMPARATOR
Intervention: Quinine infusion
Number of subjects: 94
Study 24820465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 94
Study 23682548 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy, 60 daily sessions at 1.5 atm abs, 100% oxygen, 60 minutes each.
Number of subjects: 63
Study 23682548 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging (subset of participants undergoing neuroimaging: n=17)
Number of subjects: 63
Study 20228421 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (50, 100 or 150 mg/day) for two weeks in humans
Number of subjects: 0
Study 20228421 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-enriched diets (0.05 to 2 mg/g diet) for 6 weeks in mice
Number of subjects: 0
Study 18824338 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora vaginal cream
Number of subjects: 90
Study 18824338 — intervention group
Group type: COMPARATOR
Intervention: metronidazole vaginal gel
Number of subjects: 90
Study 16390905 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine (5-20 mg/day)
Number of subjects: 32
Study 16390905 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 12584228 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b plus fixed dosing of ribavirin
Number of subjects: 0
Study 12584228 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b plus weight based dosing of ribavirin
Number of subjects: 0
Study 9890315 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone, azathioprine, heparin‐warfarin, and dipyridamole for 2 yr (group 1)
Number of subjects: 78
Study 9890315 — intervention group
Group type: COMPARATOR
Intervention: heparin‐warfarin and dipyridamole for 2 yr (group 2)
Number of subjects: 78
Study 8677032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 0
Study 8677032 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0
Study 1835989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid or recombinant alpha-interferon (2-6 months, ≥2 mega-units thrice weekly)
Number of subjects: 0
Study 1835989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid or recombinant alpha-interferon (9-18 months, variable dose)
Number of subjects: 0
Study 1835989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid or recombinant alpha-interferon
Number of subjects: 0
Study 6128084 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10 mg twice daily)
Number of subjects: 732
Study 6128084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 31914289 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transseptal suturing
Number of subjects: 40
Study 31914289 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 40
Study 30657084 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Program (HEP) for 11 weeks
Number of subjects: 58
Study 30657084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 30657084 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Program (HEP)
Number of subjects: 58
Study 27371977 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets plus topical repellent (picaridin KBR3023)
Number of subjects: 98
Study 27371977 — intervention group
Group type: COMPARATOR
Intervention: Long-lasting insecticidal nets
Number of subjects: 98
Study 24256459 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstuck and On Target (UOT)
Number of subjects: 67
Study 24256459 — intervention group
Group type: COMPARATOR
Intervention: Social skills intervention (SS)
Number of subjects: 67
Study 22855632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance for continuous sciatic nerve block
Number of subjects: 100
Study 22855632 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation (NS) guidance for continuous sciatic nerve block
Number of subjects: 100
Study 20688109 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexpensive computer-controlled olfactometer
Number of subjects: 0
Study 18307459 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 39
Study 18307459 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) with glargine
Number of subjects: 39
Study 18307459 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 39
Study 15987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 434
Study 15987919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 12629071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fixed dose, 235 MBq
Number of subjects: 88
Study 12629071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fixed dose, 350 MBq
Number of subjects: 88
Study 12629071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-adjusted dose, 2.96 MBq (80 micro Ci)/g thyroid adjusted for 24 h radioiodine uptake
Number of subjects: 88
Study 12629071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-adjusted dose, 4.44 MBq (120 micro Ci)/g thyroid adjusted for 24 h radioiodine uptake
Number of subjects: 88
Study 12629071 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose methods
Number of subjects: 88
Study 12629071 — intervention group
Group type: COMPARATOR
Intervention: Adjusted dose methods
Number of subjects: 88
Study 10506814 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac sodium eyedrops
Number of subjects: 20
Study 10506814 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 20
Study 8853810 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuit (Duraflo II)
Number of subjects: 20
Study 8853810 — intervention group
Group type: COMPARATOR
Intervention: Noncoated CPB circuit (Univox IC)
Number of subjects: 20
Study 1535185 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (thiopental adjuvant)
Number of subjects: 200
Study 1535185 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 200
Study 6228500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg t.i.d.)
Number of subjects: 16
Study 31983105 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intensity-modulated radiotherapy (IMRT) with 40-45 Gy
Number of subjects: 45
Study 31983105 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy with IMRT
Number of subjects: 45
Study 31983105 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 45
Study 31983105 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemotherapy with 3DCRT
Number of subjects: 45
Study 31983105 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy vs Radiotherapy
Number of subjects: 45
Study 29502804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus calculator (n = 14)
Number of subjects: 32
Study 29502804 — intervention group
Group type: COMPARATOR
Intervention: Standard care without a bolus calculator (n = 18)
Number of subjects: 32
Study 27325467 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 16
Study 25453516 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled Anethum Graveolens seeds
Number of subjects: 153
Study 25453516 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 153
Study 22187629 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging findings in patients with acute whiplash injury
Number of subjects: 100
Study 22187629 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 100
Study 20447857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity spine manipulation at the L4-L5 level
Number of subjects: 40
Study 20447857 — intervention group
Group type: COMPARATOR
Intervention: Control group (lying in the same position)
Number of subjects: 40
Study 20447857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity spine manipulation
Number of subjects: 40
Study 18804276 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 3196
Study 18804276 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 3196
Study 18804276 — intervention group
Group type: COMPARATOR
Intervention: No erythromycin
Number of subjects: 3196
Study 18804276 — intervention group
Group type: COMPARATOR
Intervention: No co-amoxiclav
Number of subjects: 3196
Study 15982129 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration hypothesis testing with hierarchical stimuli
Number of subjects: 0
Study 15982129 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-field effects
Number of subjects: 0
Study 15982129 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinomial model
Number of subjects: 0
Study 12027346 — intervention group
Group type: EXPERIMENTAL
Intervention: Food sharing in dyads (experimental condition)
Number of subjects: 72
Study 12027346 — intervention group
Group type: EXPERIMENTAL
Intervention: Actually feeding a morsel of food (experimental condition)
Number of subjects: 72
Study 12027346 — intervention group
Group type: EXPERIMENTAL
Intervention: Food sharing in mixed-sex or female dyads (experimental condition)
Number of subjects: 72
Study 10537435 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA step II diet plus simvastatin (mean dosage 8.11 mg/day)
Number of subjects: 0
Study 10537435 — intervention group
Group type: COMPARATOR
Intervention: AHA step II diet alone
Number of subjects: 0
Study 10537435 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation plus simvastatin
Number of subjects: 0
Study 10537435 — intervention group
Group type: COMPARATOR
Intervention: No transplantation
Number of subjects: 0
Study 7703634 — intervention group
Group type: EXPERIMENTAL
Intervention: Replenishing Qi and Invigorating Spleen (RQIS) combined with chemotherapy
Number of subjects: 61
Study 7703634 — intervention group
Group type: COMPARATOR
Intervention: Replenishing Qi and Invigorating Spleen (RQIS)
Number of subjects: 61
Study 3131389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lithium
Number of subjects: 16
Study 3131389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29512900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib at 50 mg/m² and crizotinib at 215 mg/m² once daily
Number of subjects: 25
Study 29512900 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib at 50 mg/m² and crizotinib at 130 mg/m² or 100 mg/m² twice daily
Number of subjects: 25
Study 26900386 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline 2.4 g/day for 7 days, then 2.4 g 1 hour before cycling trial
Number of subjects: 22
Study 26900386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26900386 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline 2.4 g/day
Number of subjects: 22
Study 24299932 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic variable rate phenylephrine infusion starting at 0.75 μg/kg/min (group P)
Number of subjects: 80
Study 24299932 — intervention group
Group type: COMPARATOR
Intervention: Infusion of normal saline (group S)
Number of subjects: 80
Study 22552863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension program
Number of subjects: 0
Study 22552863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension program (1 year)
Number of subjects: 0
Study 22552863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension program (6 months)
Number of subjects: 0
Study 22552863 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 20371662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg/d
Number of subjects: 19
Study 18759067 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day zinc sulfate for 2 weeks
Number of subjects: 32
Study 18759067 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg estrogen + 5 mg medroxyprogesterone acetate/day for 2 weeks
Number of subjects: 32
Study 18759067 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg estrogen + 5 mg medroxyprogesterone acetate/day and 15 mg/day zinc sulfate for 2 weeks
Number of subjects: 32
Study 18759067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no procedure)
Number of subjects: 32
Study 16463696 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (Group A)
Number of subjects: 30
Study 16463696 — intervention group
Group type: COMPARATOR
Intervention: No formal exercise training (Group B)
Number of subjects: 30
Study 12432700 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide contoured cuff
Number of subjects: 16
Study 12432700 — intervention group
Group type: COMPARATOR
Intervention: Standard width cylindrical cuff
Number of subjects: 16
Study 12432700 — intervention group
Group type: COMPARATOR
Intervention: Doppler method
Number of subjects: 16
Study 12432700 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic LOP measurement method
Number of subjects: 16
Study 12432700 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide cuff at 200 mmHg
Number of subjects: 16
Study 10355241 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8777659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide supplemented group (group N)
Number of subjects: 74
Study 1950061 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS) for 2 weeks
Number of subjects: 56
Study 1950061 — intervention group
Group type: COMPARATOR
Intervention: Bed rest for 2 weeks
Number of subjects: 56
Study 6361553 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 48
Study 6361553 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 31870049 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified anterolateral approach combined with modified posteromedial approach
Number of subjects: 108
Study 31870049 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterolateral approach combined with medial‐aided
Number of subjects: 108
Study 27110636 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 0
Study 27110636 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment-seeking comparison group
Number of subjects: 0
Study 27964747 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC) intervention
Number of subjects: 2314
Study 27964747 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution and media campaign of the Woman's Condom (WC)
Number of subjects: 2314
Study 27964747 — intervention group
Group type: COMPARATOR
Intervention: Baseline survey (quasi-control arm)
Number of subjects: 2314
Study 24407920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) for 6 months
Number of subjects: 32
Study 24407920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 21842174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Bemiparin)
Number of subjects: 141
Study 21842174 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin (LDA)
Number of subjects: 141
Study 19465285 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical IOL (Sensar AR40e)
Number of subjects: 2
Study 19465285 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Tecnis Z9000)
Number of subjects: 2
Study 19465285 — intervention group
Group type: COMPARATOR
Intervention: Both IOLs
Number of subjects: 2
Study 16875787 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1565
Study 15247754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 207
Study 15247754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 11787023 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 150
Study 11787023 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 10333390 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (normal saline at room temperature infused at 10 mL/min for 60 min, then 3 mL/min until delivery)
Number of subjects: 34
Study 10333390 — intervention group
Group type: COMPARATOR
Intervention: Control (antibiotics and acetaminophen without amnioinfusion)
Number of subjects: 34
Study 10333390 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 34
Study 10333390 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 7695166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy started one month before PTCA
Number of subjects: 0
Study 7695166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 0
Study 7695166 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2262119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg daily
Number of subjects: 399
Study 2262119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 2262119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg for attacks
Number of subjects: 399
Study 2262119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 399
Study 6892812 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine injections (2-3 mg in 10 cc saline solution 0.9%)
Number of subjects: 15
Study 31533691 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized depression risk information
Number of subjects: 700
Study 31533691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 700
Study 28864688 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus 0.5-0.8 μg/kg fentanyl
Number of subjects: 500
Study 28864688 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus 0.05-0.08 μg/kg sufentanil
Number of subjects: 500
Study 28864688 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus 0.04-0.05 mg/kg dezocine
Number of subjects: 500
Study 28864688 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus 0.04-0.05 mg/kg oxycodone
Number of subjects: 500
Study 28864688 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.4-3 mg/kg) plus 2-2.5 mL saline
Number of subjects: 500
Study 26475017 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led total sanitation (CLTS) intervention
Number of subjects: 4532
Study 25365866 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cycloferon 5% liniment and Polyoxidonium with MetrogilDenta gel
Number of subjects: 98
Study 25365866 — intervention group
Group type: COMPARATOR
Intervention: MetrogilDenta gel
Number of subjects: 98